WC
REGN icon

Wexford Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Wexford Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-278
Closed -$228K – 244
2023
Q1 		$228K Buy
+278
New +$210K 0.05% 156
2017
Q3 		– Sell
-700
Closed -$344K – 181
2017
Q2 		$344K Buy
+700
New +$306K 0.03% 143

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wexford Capital's REGN Position: Q2 2023 in Review

Wexford Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 278 shares — an estimated $228K sold.

Wexford Capital first reported a position in REGN in Q2 2017 and held it in 2 quarters. The position peaked at $344K in Q2 2017. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • Wexford Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Wexford Capital sold 278 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $228K.
  • Wexford Capital first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Wexford Capital's Regeneron Pharmaceuticals position peaked at $344K in Q2 2017.
  • 1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Wexford Capital's 13F filing for Q2 2023, filed 14 Aug 2023.